Pay in 4 interest-free payments of $7.30 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
this result was observed regardless of baseline CV risk profile, with no significant differences between subgroups (p = 0.25 for interaction between subjects with prior MI or stroke vs no prior MI or stroke and p = 0.27 for interaction between subjects with established CVD vs CV risk factors only)
Administration Routes in Research Multiple delivery methods have been investigated throughout PT-141s development: Subcutaneous injection Current FDA-approved route
Available from: [28] Sayed-Ahmed MM
Humira summary of product characteristics
US$ 22.59
US$ 28.72
US$ 21.99
US$ 28.01
US$ 20.15
US$ 26.30
